Solomon G D, Steel J G, Spaccavento L J
JAMA. 1983 Nov 11;250(18):2500-2.
We undertook a double-blind, placebo-controlled study to determine the effectiveness of verapamil hydrochloride for the prophylaxis of migraine. Twelve patients were given either verapamil hydrochloride, 80 mg four times daily, or placebo in random order during two consecutive three-month periods. Migraine frequency, severity, and duration were quantified by daily logs and monthly questionnaires. Ten of the 12 patients had fewer migraines during verapamil therapy. Migraine frequency decreased from 6.7 to 3.8 migraines per patient per month, for a mean decrease of 49%. Headache unit index fell from an average of 0.61 to 0.44. We conclude that verapamil is effective in the prophylaxis of migraine and that verapamil might be considered one alternative in the development of a regimen for the prophylaxis of migraine.
我们进行了一项双盲、安慰剂对照研究,以确定盐酸维拉帕米预防偏头痛的有效性。在连续两个三个月的期间内,12名患者被随机给予盐酸维拉帕米(每日4次,每次80毫克)或安慰剂。通过每日记录和每月问卷调查对偏头痛的频率、严重程度和持续时间进行量化。12名患者中有10名在维拉帕米治疗期间偏头痛发作次数减少。每位患者每月的偏头痛发作频率从6.7次降至3.8次,平均降幅为49%。头痛单位指数从平均0.61降至0.44。我们得出结论,维拉帕米对偏头痛预防有效,在制定偏头痛预防方案时可将维拉帕米视为一种选择。